At the ERA 2025 congress, observational studies of Benlysta (belimumab) showed meaningful improvements in renal function when added early to lupus nephritis treatment regimens. Compared to historical controls, patients experienced faster proteinuria reduction and more stable renal function when Benlysta was introduced at diagnosis. These findings support early biologic use in LN and complement controlled data from the BLISS-LN trial. While fatigue and other symptom domains were not addressed, the renal efficacy aligns with payer priorities and could guide updates to treatment algorithms in nephrology and rheumatology.

Citation: https://www.hcplive.com/view/real-world-studies-offers-insight-into-belimumab-in-lupus-nephritis-at-era-2025

Implication: Real-world renal data may strengthen Benlysta’s case for earlier use in LN treatment plans.